Scientists at the Leibniz Institute of Photonic Technology (Leibniz IPHT) have developed a new microarray-based diagnostic ...

Thermo Fisher Scientific (TMO) just posted third-quarter results that came in ahead of expectations, showing healthy revenue ...

About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Michael O'Connell, Chief Analytics Officer at Spotfire, on his journey to technology leadership in energy management ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Called the photovoltaic retina implant microarray (PRIMA), the small system uses a subretinal ... The researchers said they ...

This report provides a comprehensive analysis of the next-generation proteomics market, highlighting key trends, drivers and ...

AI translates electrical signals to the brain to help restore reading vision to treat a common form of blindness that was ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

The treatment involves inserting a tiny implant thinner than human hair under the retina. Patients then have to wear glasses that project near-infrared light to the implant.

Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...